Dr. Doris Fuertinger, Fresenius Medical Care’s Head of Computational Medicine, discusses the use of science-based systemic modeling tools to test a spectrum of hypotheses about the future impact of novel therapeutic interventions on populations with kidney disease.

Generative AI represents a paradigm shift in the landscape of healthcare, offering unprecedented potential to revolutionize patient care, diagnosis, and treatment methodologies. However, amid its promising advancements substantial and daunting risks remain. Dr. Hanjie Zhang, Senior Director of computational statistics and artificial Intelligence at the Renal Research Institute in New York discusses the benefits and risks of Generative AI in healthcare.

Dr. Giovanni Strippoli, Professor of Nephrology at University of Bari, Italy, discusses how the CONVINCE study results will contribute to reaching a higher level of certainty regarding the comparative efficacy of hemodiafiltration (HDF) versus HD in people with end-stage kidney disease.

Michelle Carver, Chief Nursing Officer and Senior Vice President of Nursing and Clinical Services at Fresenius Kidney Care discusses the benefits and challenges of patients dialyzing at home.

Luca Neri, Senior Director of Clinical Advanced Analytics at Fresenius Medical Care, discusses Anemia Management with AI and computational modeling.

Integrated evidence-generation represent a fundamental shift in the way evidence is generated across functions, geographies, and phases of the product or asset life cycle, and as such entails considerable effort to implement. Manuela Stauss-Grabo, PhD, leads the Global Biomedical Evidence Generation Team within Fresenius Medical Care’s Global Medical Office.

Rachel Meyer the Strategic Policy Advisor at the American Society of Nephrology and Sharon Pearce, Senior Vice President of Governance Affairs at National Kidney Foundation discuss the changes in U.S. policy regarding organ transplantation.

Organ Procurement and Transplantation Network (OPTN) Modernization Initiative: https://www.hrsa.gov/optn-modernization

“Dialysis Facility Profit Status and Early Steps in Kidney Transplantation in the Southeastern United States” https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216615/

“Disparities in kidney transplant waitlisting among young patients without medical comorbidities” https://pubmed.ncbi.nlm.nih.gov/37782509/

“Patient Preferences for Waiting Time and Kidney Quality” https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625104/

H.R.2923 - Living Donor Protection Act of 2023: https://www.congress.gov/bill/118th-congress/house-bill/2923?s=1&r=9

National Living Donor Assistance Center (NLDAC): https://www.livingdonorassistance.org/

H.R.6171 - Living Organ Donor Tax Credit Act of 2023: https://www.congress.gov/bill/118th-congress/house-bill/6171

By combining clinical and patient-reported end points, the CONVINCE trial is unique and affords opportunities for improving patient health status and treatment goals.

Krister Cromm, Fresenius Medical Care’s Director Person-Centered Outcomes Research, discuss the company’s evolution from disease-centered to person-centered integrated trial design.